User profiles for Verena Friedl
 | Verena FriedlPhD in Biomolecular Engineering and Bioinformatics, University of California Santa Cruz Verified email at ucsc.edu Cited by 783 |
[HTML][HTML] Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study
…, GV Thomas, AS Weinstein, V Friedl… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine prostate
cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)…
cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)…
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for
men with castration-resistant prostate cancer (CRPC). However, not all patients respond, and …
men with castration-resistant prostate cancer (CRPC). However, not all patients respond, and …
[PDF][PDF] Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway
RTK/RAS/RAF pathway alterations (RPAs) are a hallmark of lung adenocarcinoma (LUAD).
In this study, we use whole-genome sequencing (WGS) of 85 cases found to be RPA(−) by …
In this study, we use whole-genome sequencing (WGS) of 85 cases found to be RPA(−) by …
[HTML][HTML] Epigenomic blood-based early detection of pancreatic cancer employing cell-free DNA
Background & Aims Early detection of pancreatic cancer (PaC) can drastically improve survival
rates. Approximately 25% of subjects with PaC have type 2 diabetes diagnosed within 3 …
rates. Approximately 25% of subjects with PaC have type 2 diabetes diagnosed within 3 …
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer
R Aggarwal, GR Romero, V Friedl… - Prostate cancer and …, 2021 - nature.com
Background Metastatic disease burden out of proportion to serum PSA has been used as a
marker of aggressive phenotype prostate cancer but is not well defined as a distinct subgroup…
marker of aggressive phenotype prostate cancer but is not well defined as a distinct subgroup…
PLATYPUS: A multiple—view learning predictive framework for cancer drug sensitivity prediction
Cancer is a complex collection of diseases that are to some degree unique to each patient.
Precision oncology aims to identify the best drug treatment regime using molecular data on …
Precision oncology aims to identify the best drug treatment regime using molecular data on …
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate …
Objectives The net oncogenic effect of β2-adrenergic receptor ADRB2, whose downstream
elements induce neuroendocrine differentiation and whose expression is regulated by EZH2, …
elements induce neuroendocrine differentiation and whose expression is regulated by EZH2, …
Using transcriptional signatures to find cancer drivers with LURE
Cancer genome projects have produced multidimensional datasets on thousands of samples.
Yet, depending on the tumor type, 5-50% of samples have no known driving event. We …
Yet, depending on the tumor type, 5-50% of samples have no known driving event. We …
[PDF][PDF] daz püch von den chösten
V FRIEDL - mori.bz.it
Bereits im Kindesalter habe ich die Liebe zum Mittelalter, seiner Sprache und seinen
Geschichten entdeckt. Ab meinem dreizehnten Lebensjahr stieg ebenso die Zuneigung zur …
Geschichten entdeckt. Ab meinem dreizehnten Lebensjahr stieg ebenso die Zuneigung zur …
Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Using Cell-Free DNA 5-Hydroxymethylation Signatures
BACKGROUND Pancreatic cancer (PaC) has poor (10%) 5-year overall survival, largely due
to predominant late-stage diagnosis. Patients with new-onset diabetes (NOD) are at a six-to …
to predominant late-stage diagnosis. Patients with new-onset diabetes (NOD) are at a six-to …